Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 425 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05665738Recruiting
Two-visit HDR radiation to treat early prostate cancer
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
San Francisco, CaliforniaAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT02381990Recruiting
MRI- and ultrasound-guided freezing treatment for low-risk prostate cancer
This trial tests using MRI and ultrasound together to guide freezing (cryoablation) treatment for prostate cancer. It may help target the tumor more precisely while avoiding areas that could cause side effects.
Miami Lakes, FloridaAges 55 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT04895839Recruiting
Mental health coaching for men with prostate cancer
This study looks at what affects mental health while men with prostate cancer take part in a patient empowerment program. It may help you and others by testing a practical support approach delivered through email, texts, and online videos.
Ghent, East FlandersAges 18 years+ - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+ - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07672119Recruiting
Heart risks in older men on enzalutamide or darolutamide
This study looks at heart-related risks in older men with advanced prostate cancer who are taking enzalutamide or darolutamide. It may help doctors better understand how to manage heart health during treatment.
Whippany, New JerseyAges 55 years+ - NCT06363266Recruiting
Tempo program for men with prostate cancer and their caregivers
This study tests a program called TEMPO to help men with prostate cancer and their caregivers manage anxiety. You and your chosen caregiver will use an online tool designed to support your well-being.
Montreal, CanadaAges 18 years+ - NCT07406282Recruiting
Darolutamide for new prostate cancer that spread
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Cleveland, OhioAges 18 years+ - NCT07436078Recruiting
Genetic testing study for African American cancer survivors
This study offers genetic testing and counseling to African American cancer survivors. It aims to see if a culturally tailored approach helps more people understand their cancer risk and get the testing they need.
Detroit, MichiganAges 20–79 - NCT06369610RecruitingPhase 2
Less hormone therapy with radiation for prostate cancer
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05936736Recruiting
One-time radiation for prostate cancer with bladder-sparing approach
This trial tests whether giving prostate radiation in one treatment session can work well while protecting the bladder. It may help certain people with localized prostate cancer by aiming for good cancer control with fewer bladder/urinary side effects.
Milan, MIAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT07075666Enrolling by invitation
Early detection of prostate cancer in Syrian men
This trial aims to find prostate cancer early in Syrian men living in the middle region of the country. If you join, you'll help doctors learn better ways to screen for the disease, which may lead to earlier and more effective treatment.
HomsAges 40–65 - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT05765500RecruitingPhase 2
Relugolix vs leuprolide to improve prostate cancer quality of life
This Phase 2 study compares two medicines that lower testosterone—relugolix tablets versus leuprolide injections—to see which better improves quality of life. It’s for people with prostate cancer who are starting hormone treatment and have not used similar testosterone-lowering drugs before.
Boston, MassachusettsAges 18 years+ - NCT05882253Recruiting
Test MRI-guided biopsy for early prostate cancer detection
This study uses a special MRI-guided (MRI-fusion) needle biopsy to look for early prostate cancer. It may help find concerning areas more accurately before cancer spreads.
La Jolla, CaliforniaAges Any age - NCT06360523Recruiting
AI-guided MRI for prostate cancer diagnosis
This trial tests if an artificial intelligence system can improve MRI scans used to detect prostate cancer. You may join if your doctor has recommended a prostate biopsy and you have an MRI scan that can be reviewed by both radiologists and AI.
Hong KongAges 18 years+
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 425 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.